About

A commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals that address patients’ unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders.

At a glance

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs.

Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030’s.

CEO & Founder

Carl Sterritt

Shield has been transforming itself from a wholly development-focused and private company into a listed and increasingly commercially-focused, customer-facing organisation. We are now well positioned to become a fast growing, independent, international specialty pharmaceutical company and, due to the strength of our products and team, and with great thanks to all of our supportive shareholders, I look forward to the future with great excitement.

What sets us apart

  • Lead product Feraccru®

    Currently approved in Europe offers a number of important advantages compared to current standards of care for IDA. Feraccru is available through Shield Therapeutics, as well as being actively marketed by and available through, its commercial partners in Scandinavia, Switzerland and Central and Eastern Europe – with more patients than ever being treated.

  • Large market opportunities with unmet needs

    Feraccru® addresses a large and structurally growing market with significant potential in the near term.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of strong intellectual property rights including key patents in major markets. The Group’s marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD has exclusive IP rights until the mid-2030’s.